Hyperthyroxinemia: Clinical Trials

4 trials for Hyperthyroxinemia, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 recruiting, 1 active not recruiting, 1 completed. 2 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 32Active not recruiting 1, Completed 1

Follow Hyperthyroxinemia: new trials by email Literature Review of Hyperthyroxinemia trials Research Report on Hyperthyroxinemia

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Understanding, Diagnosis and Monitoring of Thyroid Hormone Action Defects
NGS sequencing, serological tests - Resistance, Thyroid Hormone
RecruitingIstituto Auxologico Italiano1502023-01-012025-09-02
A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)
Resmetirom - Non-Alcoholic Fatty Liver Disease
Phase 3Active not recruitingMadrigal Pharmaceuticals, Inc.8102021-07-092026-05-27
Register for Patients With Thyroid Hormone Resistance.
no intervention - Hypothyroidism, Global Developmental Delay
RecruitingCharite University, Berlin, Germany2002021-07-012024-08-22
A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Non Alcoholic Fatty Liver Disease Patients
Placebo, Resmetirom - Non-Alcoholic Fatty Liver Disease
Phase 3CompletedMadrigal Pharmaceuticals, Inc.13432019-12-162023-09-05

Narrower conditions

Thyroid Hormone Resistance Syndrome (4)  ·  Dyslipidemias (2)  ·  Fibrosis (2)  ·  Hyperlipidemias (2)  ·  Non-alcoholic Fatty Liver Disease (2)  ·  Allan-Herndon-Dudley syndrome (1)  ·  Dystonia (1)  ·  Hypothyroidism (1)  ·  Intellectual Disability (1)  ·  Learning Disabilities (1)  ·  Microcephaly (1)  ·  Muscle Hypotonia (1)  ·  Seizures (1)

Broader conditions

Endocrine System Diseases (4)  ·  Thyroid Diseases (4)  ·  Pathological Conditions, Signs and Symptoms (3)  ·  Digestive System Diseases (2)  ·  Fatty Liver (2)  ·  Lipid Metabolism Disorders (2)  ·  Liver Diseases (2)  ·  Metabolic Diseases (2)  ·  Nutritional and Metabolic Diseases (2)  ·  Pathologic Processes (2)  ·  Communication Disorders (1)  ·  Congenital Abnormalities (1)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1)  ·  Craniofacial Abnormalities (1)

Interventions

resmetirom (2)  ·  Serologic Tests (1)

Sponsors

Madrigal Pharmaceuticals, Inc. (2)  ·  Charite University, Berlin, Germany (1)  ·  Istituto Auxologico Italiano (1)

Countries

Puerto Rico (2)  ·  United States (2)  ·  Germany (1)  ·  Italy (1)

Top investigators

Heiko Krude, MD (1)  ·  Rebecca Taub, MD (1)  ·  Tom Hare, MD (1)

Results publications

PMID 37786277, PMID 34969638, PMID 37845512, PMID 37881807, PMID 41142528, PMID 41953252